SCHAUMBURG, Ill., July 7, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of levofloxacin injection in 5% dextrose, the generic form of the antibacterial Levaquin®, in three ready-to-use premix bag strengths. According to 2010 IMS data, the U.S. market for levofloxacin approximated $156 million.
